Patents Examined by Brian Gangle
-
Patent number: 12290559Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.Type: GrantFiled: November 14, 2022Date of Patent: May 6, 2025Assignee: Zoetis Services LLCInventors: Cassius McAllister Tucker, John David Haworth
-
Patent number: 12285469Abstract: Methods of making the M or L complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), and methods of using to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.Type: GrantFiled: March 11, 2024Date of Patent: April 29, 2025Assignee: Institute of Advanced Sciences, Inc.Inventors: Bal Ram Singh, Raj Kumar
-
Patent number: 12280035Abstract: The present invention pertains to the use of conjugated deoxynivalenol (DON) in a method to protect an animal against DON induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, liver damage, stomach ulcers and/or kidney damage as a result of the ingestion of DON.Type: GrantFiled: July 2, 2020Date of Patent: April 22, 2025Assignee: INTERVET INC.Inventors: Sietske Kooijman, Rudd Philip Antoon Maria Segers, Mateusz Walczak, Gudrun Koch, Maarten Hendrik Witlvliet
-
Patent number: 12281158Abstract: [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. [Solution] According to one aspect of the present invention, a prophylactic and/or therapeutic agent for an infectious disease or an inflammatory disease which contains an antibody recognizing apolipoprotein A2 (APOA2) as an active ingredient is provided.Type: GrantFiled: March 21, 2022Date of Patent: April 22, 2025Assignees: A-CLIP INSTITUTE, CO., LTD., NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITIONInventors: Kazuo Suzuki, Yosuke Kameoka, Yoshio Yamakawa, Fukuko Kishi, Osamu Suzuki, Minako Koura, Junichiro Matsuda
-
Patent number: 12280115Abstract: Cytokine-bisphosphonate conjugates and methods of use thereof in muscle functions.Type: GrantFiled: April 9, 2024Date of Patent: April 22, 2025Assignees: The Trustees of Columbia University in the City of New York, William Marsh Rice UniversityInventors: Gerard Karsenty, Julian Berger, Han Xiao
-
Patent number: 12274742Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: GrantFiled: November 22, 2022Date of Patent: April 15, 2025Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
-
Patent number: 12269868Abstract: It is provided novel anti-galactofuranose antibodies and their use for diagnosis of and/or treating aspergillosis, and for the design of chimeric antigen receptor T-cells, wherein single chain variable fragment of the antibodies, such as a heavy chain variable region or a light chain variable region, is fused via a spacer and a transmembrane domain to a signaling endodomain to generate an expression cassette that will be integrated into a T cell.Type: GrantFiled: December 8, 2021Date of Patent: April 8, 2025Inventors: Donald Christopher Sheppard, Benjamin Alfred William Rufus Ralph, Todd Lambert Lowary, Susmita Sarkar, Amira Ibrahim Aly Mohamed Khalil
-
Patent number: 12268734Abstract: Immunogenic proteins comprising Mycoplasma mycoides subsp. mycoides and M. mycoides subsp. capri proteins, encoding polynucleotides, a method for producing said proteins, and use of compositions to prevent M. mycoides subsp. mycoides infections are disclosed.Type: GrantFiled: January 22, 2021Date of Patent: April 8, 2025Assignees: University of Saskatchewan, International Liverstock Research Institute (ILRI), Kenya Agriculture and Livestock Research Organization (KALRO)Inventors: Andrew Potter, Volker Gerdts, Jose Perez-Casal, Yejun Wang, Hezron Wesonga, Reuben Soi, Jan Naessens, Joerg Jores
-
Patent number: 12269000Abstract: The present invention relates to a method for producing a colloid comprising functionalised liquid colloidal particles. The invention also relates to such a colloid and to the uses thereof.Type: GrantFiled: May 24, 2019Date of Patent: April 8, 2025Assignees: Paris Sciences et Lettres, Centre National de la Recherche Scientifique (CNRS), Sorbonne UniversiteInventors: Jacques Fattaccioli, Lea Pinon, Lorraine Montel
-
Patent number: 12263192Abstract: Effective and economical compositions and methods are disclosed for the treatment, and prevention of diseases and disorders associated with inflammation and/or damage to the gastrointestinal tract, including environmental enteric dysfunction. Compositions are provided comprising a synergistic combination of colostrum, immune egg, and optionally one or more additional active agents.Type: GrantFiled: February 26, 2020Date of Patent: April 1, 2025Assignee: PanTheryx, Inc.Inventors: Mark Grabowsky, Raymond J. Playford, Timothy W. Starzl, Tania Marchbank, Paul Kelly, Naheed Choudhry
-
Patent number: 12264336Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.Type: GrantFiled: December 17, 2021Date of Patent: April 1, 2025Assignee: The Regents of the University of CaliforniaInventors: Richard Klemke, Huawei Wang
-
Patent number: 12263194Abstract: A Bacillus bacterium that induces the production of interleukin-22 is provided. The Bacillus bacterium that induces the production of interleukin-22.Type: GrantFiled: March 16, 2023Date of Patent: April 1, 2025Assignees: ICHIBIKI CO., LTD., NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITYInventors: Toshihiko Kumazawa, Atsuhisa Nishimura, Noriyuki Asai, Takahiro Adachi
-
Patent number: 12257293Abstract: This invention provides methods to treat or prevent cervical dystonia, a disorder related thereto, or a symptom thereof, with novel injectable compositions comprising botulinum toxin that may be administered to a subject suffering from such maledy. The injectable compositions and methods in which these compositions are used provide novel and advantageous treatments which result in high responder rates and long duration of effect, for example, a duration of effect for 24 weeks and longer.Type: GrantFiled: December 9, 2021Date of Patent: March 25, 2025Assignee: REVANCE THERAPEUTICS, INC.Inventors: Curtis L. Ruegg, Jacob M. Waugh
-
Patent number: 12257295Abstract: Saccharide-polypeptide conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are disclosed.Type: GrantFiled: October 4, 2018Date of Patent: March 25, 2025Assignee: Pogona, LLCInventors: Bruce D. Forrest, Jack D. Love
-
Patent number: 12257235Abstract: This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and/or to treat gastrointestinal disorders are provided.Type: GrantFiled: December 12, 2023Date of Patent: March 25, 2025Assignees: Mayo Foundation for Medical Education and Research, The Regents of the University of CaliforniaInventors: Purna C. Kashyap, Michael Fischbach, Brianna B. Williams
-
Patent number: 12259396Abstract: The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.Type: GrantFiled: June 14, 2024Date of Patent: March 25, 2025Assignee: Serimmune Inc.Inventors: Patrick Sean Daugherty, Kathryn Vinaya Louise Kamath, Jack Ryan Reifert
-
Patent number: 12259378Abstract: The present invention provides methods for determining the phenotype (e.g., gain-of-function or loss-of-function) of a mutation in an ion channel or receptor by using a dynamic voltage clamp. The invention also features methods of determining whether a mutation is a gain-of-function or loss-of-function mutation and treating a disease or disorder associated with the particular gain-of-function or loss-of-function mutation.Type: GrantFiled: May 28, 2019Date of Patent: March 25, 2025Assignee: Praxis Precision Medicines, Inc.Inventor: Steven Petrou
-
Patent number: 12259397Abstract: Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.Type: GrantFiled: March 19, 2020Date of Patent: March 25, 2025Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Paulo Artur Chaves Fontes, John A. Kellum
-
Patent number: 12257272Abstract: A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach.Type: GrantFiled: March 15, 2022Date of Patent: March 25, 2025Assignee: Seed Health, Inc.Inventor: Joseph E. Kovarik
-
Patent number: 12252532Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease, in increasing mass of muscle tissue or in increasing strength of muscle tissue.Type: GrantFiled: May 12, 2022Date of Patent: March 18, 2025Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Yoshinao Ruike, Taichi Kuramochi